vietexplorer0016

2024: A Year of Resilience and Market Leadership in the Face of Volatility Mr. Sung Min Woo, Chairman of the Board of Directors (BOD), set the tone for the AGM with his opening remarks: “2024 was a year of global uncertainty and market volatility. However, through the unified efforts of our Board of Management and dedicated employees, Imexpharm achieved remarkable results, outperforming the market. As we move forward, 2025 marks a pivotal year in our long-term vision to become a leading Asian pharmaceutical company, with a focus on high-tech, high-value-added products that can compete on a global scale.” Imexpharm’s performance in 2024 was impressive, with a net revenue of VND2,205 billion, reflecting an 11% year-on-year increase. The ETC channel shone with a remarkable 56% growth, and revenue from EU-GMP standard injectable products contributed significantly, accounting for 33% of the total. EBITDA climbed to VND521 billion, a 12% increase, and the EBITDA margin stood at an impress...